ModerateOther antibacterials×Atypical antipsychotics
Updated · Methodology
Mechanism
Quetiapine is extensively metabolised in the liver, mainly by CYP3A4, and its metabolites are excreted in urine and faeces (Seroquel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Fosfomycin is not metabolised and is excreted by the kidneys (oral fosfomycin SmPC, AEMPS, section 5.2), so the drugs share no metabolic pathway. The link is electrolytes. The quetiapine SmPC calls for caution with drugs known to cause electrolyte imbalance or prolong the QT interval, especially in hypokalaemia or hypomagnesaemia (AEMPS, sections 4.4 and 4.5). According to its SmPC, intravenous fosfomycin can lower serum potassium and, because of its high sodium content, carries a risk of hypernatraemia (Fosfocina SmPC, AEMPS, section 4.4). The oral fosfomycin SmPC describes no such effects.
Symptoms
The documents describe no symptoms specific to the combination. Intravenous fosfomycin can lower potassium, and the sodium load of the solution can cause hypernatraemia and fluid overload, especially in heart failure, cirrhosis, nephrotic syndrome and hypertension (Fosfocina SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Quetiapine causes somnolence and dizziness, and its QT prolongation warning applies especially in hypokalaemia or hypomagnesaemia (Seroquel SmPC, AEMPS, section 4.4).
Management
With intravenous fosfomycin, quetiapine is used with caution, because the quetiapine SmPC calls for caution with drugs known to cause electrolyte imbalance (Seroquel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Sodium and potassium are checked regularly during intravenous fosfomycin, especially in prolonged treatment, and potassium supplementation should always be considered (Fosfocina SmPC, AEMPS, section 4.4). Before intravenous fosfomycin is started, the risk of sodium and fluid overload is assessed, a low-sodium diet is recommended, and if needed the infusion is lengthened or the single dose reduced and given more often (Fosfocina SmPC, AEMPS, section 4.4). With oral fosfomycin, the documents call for none of these measures. The combination is acceptable without dose changes, and fosfomycin is taken on an empty stomach or 2–3 hours after a meal (oral fosfomycin SmPC, AEMPS, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Seroquel 25 mg, quetiapina (nº registro 63054), secciones 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 63054, revisión 12/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Fosfomicina, Fosfocina 4 g polvo para solución para perfusión (nº registro 50878), sección 4.4 (2023)– AEMPS, CIMA, nº registro 50878 (Fosfocina 4 g polvo para solución para perfusión), revisión 02/2023, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Fosfomicina, Fosfomicina Cinfa 3 g granulado para solución oral (nº registro 82353), sección 4.5 (2022)– AEMPS, CIMA, nº registro 82353 (Fosfomicina Cinfa 3 g granulado para solución oral en sobres EFG), revisión 10/2022, secciones 4.3, 4.4, 4.5 y 5.2